1. Introduction

Despite all improvements in diagnostic imaging modalities, antibiotic regimens, and surgical methods, the frequency of Staphylococcus aureus infective endocarditis (SAIE) increases constantly and is associated with poor prognosis.

1.1. Aim of work

To update current knowledge on the epidemiology and the echocardiographic profile of SAIE in Tunisian hospital, and to determine the prognosis and predicting factors of mortality during this affection.

2. Methods

This was a retrospective study which included 230 consecutive patients diagnosed with infective endocarditis (IE) and hospitalized in the cardiology department of Rabta hospital between 1996 and 2016. SAIE accounts for 30% of cases (70 patients). We included patients who were diagnosed with definite infective endocarditis based on the modified Ducke criteria. Patients diagnosed with ‘possible IE’ based on these same criteria were excluded.

The patients were divided into two groups according to the date of diagnosis: group A (30 patients from January 1996 to June 2006) and group B (40 patients from June 2006 to December 2016). These groups were compared for epidemiologic factors, echocardiographic factors, and clinical outcome differences.

Data was extracted from the medical records of the patients. We analyzed the following informations: age, gender, comorbidities, conditions which predispose patients for IE, imaging assessment (transthoracic echocardiography (TTE) and/or...
transesophageal echocardiography (TEE), cerebral tomography scan data), cardiac complications of SAIE, surgical treatment regimens, early outcome of IE, and in-hospital mortality data.

Tomography scan imaging was performed in 40% of cases: 8 patients in group A (28% of cases) and 20 patients in group B (50% of cases).

3. Statistical analysis

Quantitative variables are expressed as means ± the standard deviation. The normal distribution of variables was verified with the Shapiro-Wilk test.

Comparison between groups were carried out using Student’s t-test or the Chi² test depending on the nature of quantitative or qualitative variables.

Single-variable then multivariate analyses were conducted in order to determine factors predicting mortality using a logistic regression model. A p-value under 0.05 was considered significant for all tests.

4. Results

The male-to-female ratio was 1.91. The mean age was 39 ± 10 years. SAIE involved prosthetic valve or surgical valve repair in 16 patients (23%) and a native valve in 54 patients (77%). Rheumatic heart disease was the most common predisposing factor for SAIE (95%). Four patients (5%) had degenerative valvular disease.

A debilitated clinical setting was observed in 32 patients (45%) of cases. Diabete (n = 17), cirrhosis (n = 6), and severe chronic renal failure (n = 9) were the most common ones. The means of entry was identified in 38 of cases (55%). Two of these were cutaneous (n = 36) and digestive (n = 2). Staphylococcus aureus was resistant to meticillin in 12 patients (17%). A combination of the two imaging modalities (TTE and TEE) demonstrated the presence of vegetation in 92% of patients, with an average size of 20 mm [05–35 mm]. Both valve abscess and valve mutilation were present in 14 patients (20%). A prosthetic valve dehiscence with severe regurgitation in 92% of patients, with an average size of 20 mm [05–35 mm].

Timing of surgery for valve replacement or valve repair. The average waiting (n = 21, 30% of cases). Thirty two patients (45%) underwent early surgery.

A prosthetic valve dehiscence with severe regurgitation in 7 patients (10%). Both valve abscess and valve mutilation were present in 14 patients (20%). A prosthetic valve dehiscence with severe regurgitation was observed in 7 patients (10%).

The most frequently reported complications were congestive heart failure (n = 35, 50% of cases), systemic embolism including central nervous systemic (CNS) and spleen location (n = 28, 40% of cases), neurological events (n = 26, 38% of cases), and sepsis (n = 21, 30% of cases). Thirty two patients (45%) underwent early surgery for valve replacement or valve repair. The average waiting time for surgery was 10 days with extremes ranging from 1 to 21 days. The rate of in-hospital mortality was 27% (n = 19).

Factors associated with in-hospital mortality through single-variable analysis (Table 1) were: age, prosthetic valve endocarditis, abscess, heart failure, severe sepsis, neurological complications, systemic embolic, and methicillin resistant (meti R) staphylococcus infection. Early surgery was associated with significantly lower hospital mortality.

Independent factors of hospital mortality during SAIE were: prosthetic valve endocarditis, abscess, septic complications, heart failure, and systemic embolism. Early surgery was significantly associated with lower hospital mortality (Table 2).

There was not a significant difference between the two periods of study concerning the age, sex, incidence of rheumatic valve disease, or the prosthetic IE associated with the patients (Table 3). Between the two period of study, there were no significant decreases in the proportions of annular abscess, vegetation, and valve perforation. Heart failure and neurological events rates were stable and similar in the two groups.

There was a significant decrease in the proportions of sepsis whereas the systemic embolism rate tended to increase over time. The early surgery rate increased significantly between the two consecutive periods. The in-hospital mortality is lower in group B (Table 3).

5. Discussion

The major findings of our study are as follows (1) Rheumatic valve disease was the predominant predisposing heart disease for SAIE, (2) the most common complication by far was heart failure (50%), (3) the global in-hospital mortality rate of SAIE continues to be high (27%), (4) independent factors of in-hospital mortality

### Table 2
Predictor factors of mortality in multivariate analysis.

| Predictor                  | OR     | CI         | p     |
|----------------------------|--------|------------|-------|
| Age                        | 1.2    | [1–1.34]   | 0.8   |
| Prosthetic IE              | 2.2    | [1.2–3.9]  | 0.006 |
| Abscess                    | 1.7    | [1.1–3.3]  | 0.03  |
| Meti R Staphylococcus      | 1.5    | [0.8–2.9]  | 0.2   |
| Heart failure              | 5.2    | [2–14.7]   | 0.001 |
| Sepsis                     | 3.4    | [1.8–5]    | 0.04  |
| Systemic embolism          | 2.5    | [1.1–7.5]  | 0.04  |
| Neurological complications | 0.76   | (0.38–3)   | 0.25  |
| Early surgery              | 0.4    | (0.22–0.7) | 0.003 |

### Table 3
Patients characteristics: comparison between two groups A and B.

|                       | Group A n : 30 | Group B n : 40 | p     |
|-----------------------|----------------|----------------|-------|
| Age                   | 35 ± 10        | 36 ± 9         | 0.8   |
| Gender (M/F)          | 20/10          | 25/15          | 0.5   |
| Rheumatic valve disease | 24 (80%)  | 27 (76)        | 0.6   |
| Diabete               | 6 (20%)        | 11 (27.5%)     | 0.55  |
| Cirrhosis             | 3 (10%)        | 3 (7.5%)       | 0.7   |
| Severe renal failure  | 3 (10%)        | 6 (15%)        | 0.6   |
| Prosthetic endocarditis | 5 (17%)    | 11 (27%)       | 0.1   |
| Abssess               | 3 (10%)        | 11 (28%)       | 0.680 |
| Végétation            | 24 (80%)       | 40 (100%)      | 0.580 |
| Perforation           | 5 (16%)        | 9 (22.5%)      | 0.7   |
| 0.04                  |                |                |       |
| Dehiscence of prosthetic | 3 (30%)   | 4 (10%)        | 0.06  |
| Meti R staphylococcus | 3 (10%)        | 6 (15%)        | 0.4   |
| Heart failure         | 15 (30%)       | 20 (50%)       | 0.06  |
| Sepsis                | 13 (43%)       | 8 (20%)        | 0.04  |
| Neurological complication | 11 (37%)    | 15 (37.5%)     | 0.06  |
| Systemic embolism     | 8 (28%)        | 20 (50%)       | 0.04  |
| Early surgery         | 8 (26.66%)     | 24 (60%)       | 0.01  |
| Hospital mortality (%)| 13 (43%)       | 5 (13%)        | 0.04  |
are: prosthetic valve endocarditis, abscess, septic complications, heart failure, and systemic embolisms. Early surgery was significantly associated with lower in-hospital mortality. (5) comparison of the two periods revealed an increase in systemic embolism rate and a need for earlier surgery and a decrease in the rate of in-hospital mortality.

*Staphylococcus aureus* is the leading cause of infective endocarditis (IE) in many regions of the world.1–3 It is a malignant disease which has now emerged as a dominant cause of IE.4 The frequency of SAIE increases constantly and was recently estimated at between 25% and 50% of all cases of IE.5,6 In our study, SAIE accounted for 30% of cases of IE.

SAIE occurs in a more debilitated clinical setting, including chronic renal failure, hemodialysis, diabetes mellitus, hematologic malignancy, and immunodepression.7–9 This finding was also reported in 45% of cases in this study. SAIE remains a disease with high incidences of complications.10–11 Cardiac failure may be present on admission or, more frequently, develops during hospitalization in 28–41% of patients with left-sided endocarditis.12 In our study, a high frequency of heart failure cases was reported because we had included a prosthetic valve dehiscence cases that frequently developed heart failure signs.

Previous studies have noted a higher incidence of neurological events in patients with *S. aureus*13–17 and estimate that 43.3% of patients with SAIE presented a neurological complication rate 2–3 times higher than that observed with other pathogens.18 The high rate of 38% for neurological complications observed in our study corroborates the findings of other studies.

The true incidence of embolic events in our study may have been underestimated (40%) because of a less frequently-used imaging technique (scan tomography).

*S. aureus* is a malignant disease known to be responsible for severe sepsis4,8 and poor prognosis.19 In this study, we reported this complication in 20% of patients.

Early Surgery has become a necessity in the therapy of complicated IE.20,21 It was performed in our study in 45% of patients, compared with 26.2% in published series on both right and left-sided native-valve SAIE.22 This rate may be explained by the fact that we had included prosthetic endocarditis in our study.

Fiederspiel et al.23 recently reported nearly a 60% increased risk of in-hospital mortality from SAIE compared with streptococcal and enterococcal endocarditis.

In-hospital mortality rates range between 30% and 71% according to various authors.23 The in-hospital mortality rate in our study was 27%. Abdallah reported similar results24 when including all types of SAIE (i.e. prosthetic valve, pacemaker, etc.), which ranged from 20% to 37%. The high in-hospital mortality rate reported in our study was due to the high frequency of complications.

Prosthetic infective endocarditis, abscess, severe sepsis, congestive heart failure, systemic embolism events, and the lack of early surgery were the risks factor of mortality. These same risk factors were also found in many series.5,7,10

*S. aureus* prosthetic valve infective endocarditis (SA PVIE) is a factor associated with high mortality rates reported in our study and several others.25,26

As previously reported in published series devoted to right and left-sided native-valve SAIE,12 heart failure is a powerful predictor of in-hospital mortality.

Severe sepsis is a major prognostic predictor of in-hospital mortality and long-term mortality because severe cases progress towards multiorgan dysfunction, disseminated intravascular coagulation, lactic acidosis, and death.27,28,29

Hoen and colleagues suggested that the decrease in the rate of in-hospital mortality observed in a 10-year interval may have been related to a higher rate of cardiac surgery. Similarly, Lalani et al.28 reported that patients with SAIE undergoing early surgery had a risk reduction of in-hospital mortality of 20.1% compared with patients treated medically. Similar results were found in this study.

The severe sepsis rate decreased significantly over time, which may be due to better management of antibiotics. The systemic embolism rate tended to increase because of an increased use of systemic tomodigraphy in group B (26% in group A, versus 50% in group B). The early surgery rate increased significantly between the two consecutive periods because of higher complications in group B. In-hospital mortality decreased over time thanks to better medical and surgical strategies within a multidisciplinary team.30

5.1. Limits of our study

- Our study is retrospective and therefore is inevitably subject to bias.
- The long period of the study was imposed by the rarity of this disease.
- The low number of patients despite the long period of study can also be explained by the strict selection criteria.
- Future prospective, multicenter studies are required to validate the results of our study

6. Conclusion

Despite therapeutic advances, SAIE is still a potentially life-threatening infection associated with high mortality and morbidity rates. It is primarily associated with poor prognosis related to comorbidities, heart failure, as well as septic and embolic events due to the pathogen’s aggressive destructive nature.

7. Abbreviation

- *Staphylococcus aureus* Infective Endocarditis (SAIE)
- Infective Endocarditis (IE)
- methicillin Resistant (meti R)
- Transthoracic Echocardiography (TTE)
- Transesophageal Echocardiography (TEE)
- *Staphylococcus aureus* Prosthetic Valve Infective Endocarditis (SA PVIE)

Conflicts of interest

The authors declare no conflict of interest.

Authors’ contributions

All authors had contributed in writing this article.

References

1. Fowler Jr VG, Miro JM, Hoen B, et al. *Staphylococcus aureus* endocarditis: a consequence of medical progress. *JAMA* 2005;293(12):1233–1241.
2. Hoen B, Alla F, Selton-Suty C, Béguint I, Bouvet A, Briançon SJ. Changing profile of infective endocarditis. Re- sults of a 1-year survey in France. *JAMA* 2002;288:75–81.
3. Cabell CH, Jolis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. *Arch Intern Med* 2002;162:90–94.
4. Mourvillier B, Trouillet JL, Timsit JP, et al. Infective endo- carditis in the intensive care unit: clinical spectrum and prognostic factors in 228 consecutive patients. *Intensive Care Med* 2004;30:2046–2052.
5. Hogevik H, Olaison L, Andersson R, Lindberg J, Alestig K. Epidemiologic aspects of infective endocarditis in an urban population. A 5-year prospective study. *Medicine (Baltimore)* 1995;74:324–329.
6. Chu VH, Cabell CH, Benjamin Jr D, et al. Early predictors of in-hospital death in infective endocarditis. *Circulation* 2004;109:1745–1749.
7. Petti CA, Fowler VG, *Staphylococcus aureus* bacteremia and endocarditis. *Infect Dis Clin N Am.* 2002;16:413–435.
8. Fowler Jr G, Miro JM, Hoen B, et al.. *Staphylococcus aureus* endocarditis: a consequence of medical progress. *JAMA*. 2005;293:3012–3021.
9. Petti A, Fowler Jr VG. *Staphylococcus aureus* bacteremia and endocarditis. *Infect Dis Clin North Am*. 2002;293:413–435.
10. Miro M, Anguera I, Cabell CH, et al.. *Staphylococcus aureus* native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. *Clin Infect Dis*. 2005;45:507–514.
11. Fernandez Guerrero ML, Gonzalez Lopez JJ, Goyenechea A, et al.. Endocarditis caused by *Staphylococcus aureus*: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. *Medicine (Baltimore)*. 2009;88:1–22.
12. Nadji G, Remadi JP, Covioux F, et al.. Comparison of clinical and morphological characteristics of *Staphylococcus aureus* endocarditis with endocarditis caused by other pathogens. *Heart*. 2005;95:912–917.
13. Remadi P, Habib G, Nadji G, et al.. Predictors of death and impact of surgery in *Staphylococcus aureus* infective endocarditis. *Ann Thorac Surg*. 2007;83:1295–1302.
14. Kulikova N, Garbasova M, Sokolova J, et al.. *Staphylococcus aureus* in the aetiology of infective endocarditis in Slovakia during the last six years. *Int J Antimicrob Agents*. 2013;41:57–58.
15. Kanter MC, Hart RG. Neurologic complications of infective endocarditis. *Neurology*. 1991;41:1015–1020.
16. Heiro M, Nikoskelainen J, Engblom E, et al.. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. *Arch Intern Med*. 2000;160:2781–2799.
17. Thuny, Di Salvo G, Belliard O, et al.. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. *Circulation*. 2005;112:69–77.
18. Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B, et al.. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. *Circulation*. 2013;127:2272–2284.
19. Fernandez GML, Lopez G, Goyenechea A, et al.. *Staphylococcus aureus* endocarditis caused by *Staphylococcus aureus*: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. *Medicine (Baltimore)*. 2009;88:1–22.
20. Hasbun R, Vikram HR, Barakat LA, et al.. Complicated left-sided native valve endocarditis in adults: risk classification for mortality. *JAMA*. 2003;289:1933–1940.
21. Netzer ROM, Altwegg SC, Zollinger E. Infective endocarditis: determinants of long term outcome. *Heart*. 2002;88:61–66.
22. Federspiel J, Stearns SC, peppercorn AF. Increasing US rates of endocarditis with *Staphylococcus aureus*: 1999–2008. *Arch Intern Med*. 2012;172:363–365.
23. Gouello JP, Asfar P, Brenet O. Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases. *Crit Care Med*. 2000;28:377–382.
24. Abdallah L, Remadi JP, Gilbert H, et al.. Long-term prognosis of left-sided native-valve *Staphylococcus aureus* endocarditis. Pronostic à long terme de l’endocardite infectieuse à staphylocoque doré sur valve native du cœur. *Arch Cardiovasc Dis*. 2016;109:260–276.
25. John MD, Hibberd PL, Karchmer AW, et al.. *Staphylococcus aureus* prosthetic valve endocarditis: optimal management and risk factors for death. *Clin Infect Dis*. 1998;26:1302–1309.
26. Chirouze C, Cabell C, Fowler Jr V. Prognostic Factors in 61 Cases of *Staphylococcus aureus* prosthetic valve infective endocarditis from the international collaboration on endocarditis merged database. *Clin Infect Dis*. 2004;38:1323–1327.
27. Wolff M, Witchitz S, Chastang C, Regnier B, Vachon F. Prosthetic valve endocarditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision. *Chest*. 1995;108:688–694.
28. Bone RC. Gram-positive organisms and sepsis. *Arch Intern Med*. 1994;154:26–326.
29. Lalani T, Cabell CH, Benjamin DK, et al.. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. *Circulation*. 2010;121:1005–1101.
30. Habib Gilbert, Lancellotti Patrizio, Antunes Manuel J, Bongiorni Maria Grazia. ESC guidelines for the management of infective endocarditis. *Eur Heart J*. 2015;2015(36):3075–3130.